In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Sagimet Biosciences Inc (NASDAQ: SGMT) closed at $7.87 in the last session, down -9.54% from day before closing price of $8.7. In other words, the price has decreased by -$9.54 from its previous closing price. On the day, 1.7 million shares were traded. SGMT stock price reached its highest trading level at $8.7 during the session, while it also had its lowest trading level at $7.63.
Ratios:
We take a closer look at SGMT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 20.26 and its Current Ratio is at 20.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on December 06, 2024, initiated with a Outperform rating and assigned the stock a target price of $30.
On November 12, 2024, UBS started tracking the stock assigning a Buy rating and target price of $12.
Goldman Downgraded its Buy to Neutral on June 28, 2024, whereas the target price for the stock was revised from $23 to $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 23 ’24 when Kemble George sold 23,625 shares for $3.17 per share. The transaction valued at 74,830 led to the insider holds 118,693 shares of the business.
Martins Eduardo Bruno sold 8,357 shares of SGMT for $25,910 on Jul 19 ’24. The Chief Medical Officer now owns 81,213 shares after completing the transaction at $3.10 per share. On Jul 19 ’24, another insider, Rozek Elizabeth, who serves as the General Counsel and CCO of the company, sold 10,914 shares for $3.10 each. As a result, the insider received 33,830 and left with 160,506 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMT now has a Market Capitalization of 253377008 and an Enterprise Value of 135569504.
Stock Price History:
The Beta on a monthly basis for SGMT is 3.33, which has changed by 1.4905064 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, SGMT has reached a high of $10.43, while it has fallen to a 52-week low of $1.73. The 50-Day Moving Average of the stock is 71.55%, while the 200-Day Moving Average is calculated to be 79.28%.
Shares Statistics:
According to the various share statistics, SGMT traded on average about 1.48M shares per day over the past 3-months and 2330040 shares per day over the past 10 days. A total of 30.67M shares are outstanding, with a floating share count of 23.77M. Insiders hold about 26.17% of the company’s shares, while institutions hold 36.23% stake in the company. Shares short for SGMT as of 1749772800 were 3805939 with a Short Ratio of 2.57, compared to 1747267200 on 3586791. Therefore, it implies a Short% of Shares Outstanding of 3805939 and a Short% of Float of 13.4.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Sagimet Biosciences Inc (SGMT) is currently being evaluated by 7.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.57, with high estimates of -$0.25 and low estimates of -$0.94.
Analysts are recommending an EPS of between -$1.32 and -$3.56 for the fiscal current year, implying an average EPS of -$2.24. EPS for the following year is -$2.57, with 7.0 analysts recommending between -$1.27 and -$4.16.
